Hologic (NASDAQ: HOLX) specializes in women’s health and operates in four business segments:
- Breast Health 31%
- Diagnostics 32%
- GYN Surgical 17%
- Skeletal Health 3%
The company was a pioneer in digital mammography taking on the big conglomerates like GE and Siemens AG who had much larger and better-established radiology divisions. Hologic’s early growth was astronomic.
Part of that growth was through business mergers and acquisitions. They made six more »
This week Hologic (NASDAQ: HOLX) announced it would acquire Gen-Probe (NASDAQ: GPRO) for $3.7 billion or $82.75/share, a 20% premium based on last Friday’s close, representing ~6.0x CY 2012 revenue and ~23.0x CY 2012EBITDA, pre-synergies. The transaction financing will be all-cash and is expected to close later this year. The companies are projecting $75 million in synergies over three years, making the deal theoretically more »
Johnson & Johnson (NYSE: JNJ) gave results recently and underperformed the broader market on what was a strong up day. There wasn't anything inherently wrong in the numbers, but there wasn't anything sexy about them either. Revenues were slightly down, with a negative currency effect of 1.2% not helping matters. However, top line growth is not the key for JNJ.
JNJ’s attraction is of the kind that more »